MedPath

Study for correlation between changes in stimulatory immune checkpoints of peripheral blood lymphocyte and efficacy before and after treatment with PD-1 for advanced NSCLC patients

Not Applicable
Not yet recruiting
Conditions
SCLC
Registration Number
ITMCTR1900002416
Lead Sponsor
Shanxi Provincial Hospital of Traditional Chinese Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

1. Aged greater than or equal to 18 years;
2. Histopathology is clearly diagnosed as NSCLC;
3. Clinical stage is stage IV;
4. ECOG score is 0 to 2 points;
5. There are evaluable lesions.

Exclusion Criteria

1. There have been acute cardiogenic diseases or chronic basic diseases, which may interfere with treatment after evaluation;
2. previous severe liver and kidney dysfunction;
3. end stage, inability to tolerate PD-1 treatment;
4. patients autoimmune system disease.

Study & Design

Study Type
Basic Science
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.